Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis. Issue 4 (April 2022)

• Record Type: Journal Article
• Authors: Bülow, Nathalie Søderhamn; Dreyer Holt, Marianne; Skouby, Sven Olaf; Birch Petersen, Kathrine; Englund, Anne Lis Mikkelsen; Pinborg, Anja; Macklon, Nicholas Stephen
• Is Part Of: Reproductive biomedicine online. Volume 44:Issue 4(2022)
• Page Start: 717
• Page End: 736
• Publication Date: 2022-04
• Subjects: Human reproductive technology -- Periodicals; Human embryo -- Periodicals; Reproduction -- Periodicals; 616.692
• DOI: 10.1016/j.rbmo.2021.12.006
• Languages: English
• ISSNs: 1472-6483

Abstract

Abstract: Letrozole reduces serum oestradiol by inhibiting the aromatase enzyme and has growing clinical indications in fertility. The available evidence of letrozole's role in ovarian stimulation for IVF and intracytoplasmic sperm injection (ICSI) and clinical outcomes was assessed. Medline, Cochrane, and ClinicalTrials.gov databases were systematically searched up until August 2021, including 31 studies ( n = 16 randomized controlled trials [RCTs]; n = 15 observational studies). Live birth rate (LBR) in poor responders significantly increased by 7% (95% CI, 1% to 13%, P = 0.03) with letrozole co-treatment. Concomitantly, the gonadotrophin consumption was significantly reduced, without decreasing the number of retrieved oocytes. In normal responders, number of oocytes increased with 1.8 oocytes (95% CI 0.35 to 3.27, P = 0.01) with letrozole co-treatment. No significant effect on LBR, clinical pregnancy rate (CPR), or ovarian hyperstimulation syndrome rate was demonstrated. Only two studies reported on high responders and revealed no effect on LBR or CPR. Overall, the endometrium thickness was slightly affected, where as the, miscarriage rate and cancellation rate were unaffected by letrozole co-treatment. None of the included studies reported on neonatal outcomes. The quality of evidence was high or moderate in the RCTs and low in the observational studies. In conclusion, poor responders may benefit from co-treatment with letrozole during ovarian stimulation for IVF, whereas letrozole for normal and high responders requires further investigation with larger, high-quality studies.